Personalized Neoantigen mRNA Vaccines Targeting Hard to Treat Cancers
Cancer vaccines train the immune system to recognize and attack tumor cells. Neoantigen vaccines focus on unique mutations found only in a patient’s cancer. mRNA technology delivers instructions for these neoantigens, so the body produces them and generates a targeted immune response. Researchers are testing these personalized vaccines against cancers that respond poorly to standard treatments, such as melanoma, pancreatic cancer, and glioblastoma.
In high-risk resected melanoma, an individualized mRNA neoantigen vaccine combined with pembrolizumab has shown strong results. Early studies reported a roughly 49 percent reduction in recurrence risk and a 59 percent reduction in distant metastasis risk compared with immunotherapy alone. Benefits held through several years of follow-up. A phase 3 trial later confirmed significant improvements in recurrence-free and distant metastasis-free survival. The vaccine encodes up to 34 patient-specific neoantigens identified from tumor sequencing. As a result, it aims to expand and sustain T-cell responses against residual disease.
Pancreatic ductal adenocarcinoma remains one of the most lethal solid tumors, with high recurrence rates after surgery. Personalized mRNA vaccines have produced encouraging early signals. In a phase 1 study, patients who developed strong T-cell responses to the vaccine showed longer recurrence-free survival than non-responders. Some responders remained free of recurrence for years. The approach sequences the resected tumor, selects neoantigens, and encodes them into mRNA. Chemotherapy and checkpoint inhibitors are often given alongside the vaccine. Randomized trials are now testing whether these immune responses translate into broader clinical benefit.
Similar strategies are under investigation in other difficult cancers. Personalized neoantigen vaccines combined with PD-1 blockade have generated durable T-cell responses in newly diagnosed glioblastoma. Trials are also evaluating mRNA neoantigen therapies in non-small cell lung cancer, bladder cancer, and colorectal cancer. Some studies explore off-the-shelf vaccines that target shared mutations such as KRAS. These may offer faster production than fully individualized products.
Manufacturing remains a practical challenge. Each personalized vaccine requires tumor sequencing, neoantigen selection, and custom mRNA production, which currently takes several weeks. Therefore, most programs focus on the adjuvant setting after surgery, when microscopic residual disease can be targeted. Researchers continue to improve neoantigen prediction algorithms and production timelines. Combination with checkpoint inhibitors appears important because it helps prevent tumors from suppressing the vaccine-induced T cells.
Neoantigen and mRNA cancer vaccines represent a promising shift toward truly personalized immunotherapy. Early and mid-stage data show that they can generate lasting immune responses and reduce recurrence in selected patients with hard-to-treat cancers. Larger confirmatory trials will determine how widely these approaches can improve survival. When successful, they may expand treatment options for cancers that have long resisted conventional therapies.